Core Insights - Charles River Laboratories International, Inc. (CRL) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.34, a 3.1% increase year over year, exceeding the Zacks Consensus Estimate by 13.6% [1] - Total revenues for the first quarter reached $984.2 million, surpassing the Zacks Consensus Estimate by 5.2%, but reflecting a 2.4% decline from the previous year [2] - The company raised its 2025 guidance, indicating improved net bookings in the Discovery and Safety Assessment (DSA) segment [12] Financial Performance - The gross profit for the quarter was $317.7 million, down 7.9% from the prior year, with a gross margin of 32.3%, contracting 181 basis points year over year [7] - Selling, general & administrative expenses decreased by 4.6% year over year to $177.8 million, while adjusted operating profit fell 11.7% to $139.9 million [7] - The company exited the first quarter with cash and cash equivalents of $229.4 million, an increase from $194.6 million at the end of the previous quarter [8] Segment Performance - Research Models and Services (RMS) revenues totaled $213.1 million, down 3.5% year over year, primarily due to timing of shipments in China and lower revenues in the Cell Solutions business [4] - Discovery and Safety Assessment (DSA) revenues amounted to $592.6 million, a decline of 2.1% year over year, attributed to lower revenues for discovery services [5] - Manufacturing Solutions revenues were $178.5 million, down 3.6% year over year, mainly due to declines in CDMO and Biologics Testing businesses [6] Shareholder Returns - During the first quarter, the company repurchased 2.1 million shares for a total of $350 million, with a remaining authorization of $549.3 million under its $1 billion stock repurchase program [9] 2025 Guidance - For 2025, CRL expects total revenues to decline in the range of 5.5%-3.5%, an improvement from the earlier estimate of 4.5%-7% [10] - Adjusted EPS for 2025 is projected to be in the range of $9.30-$9.80, up from the previous range of $9.10-$9.60 [11]

Charles River Laboratories International (CRL) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Company Participants Todd Spencer - Vice President, Investor RelationsJames Foster - Chairman, President and CEOFlavia Pease - Corporate Executive VP & CFOElizabeth Anderson - Senior Managing DirectorDave Windley - Managing DirectorMichael Ryskin - Managing DirectorKyle Crews - Equity Research AssociatePatrick Donnelly - Managing DirectorCasey Woodring - Vice President - Equity ResearchCharles Rhyee - Managing Dire ...

Charles River Laboratories International (CRL) Q1 2025 Earnings Call May 07, 2025 09:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by, and welcome to the Charles River Laboratories First Quarter twenty twenty five Earnings Conference Call. This call is being recorded. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. I would now like to turn the conference over to our host, Todd Spencer, Vice President of ...

Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.59%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $2.50 per share when it actually produced earnings of $2.66, delivering a surprise ...

Charles River Laboratories 1Q 2025 Results May 7, 2025 © 2025 Charles River Laboratories International, Inc. Safe Harbor Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other similar expressions that p ...

Financial Performance - First-quarter revenue for Charles River Laboratories was $984.2 million, a decrease of 2.7% from $1,011.6 million in Q1 2024[2]. - GAAP earnings per share (EPS) for Q1 2025 was $0.50, down from $1.30 in Q1 2024, while non-GAAP EPS increased to $2.34, up 3.1% from $2.27[4][5]. - The GAAP operating margin decreased to 7.6% from 12.5% in Q1 2024, while the non-GAAP operating margin increased to 19.1% from 18.5%[3]. - Total revenue for the three months ended March 29, 2025, was $984.168 million, a decrease of 2.5% compared to $1,011.560 million for the same period in 2024[30]. - Service revenue decreased to $797.923 million, down 2.3% from $816.862 million year-over-year[30]. - Net income attributable to Charles River Laboratories was $25.469 million, a significant decline of 65.1% from $72.960 million in the prior year[30]. - Earnings per share (EPS) for the quarter was $0.50, down from $1.31 in the same quarter last year[30]. - Operating income fell to $74.669 million, a decrease of 40.7% compared to $125.977 million in the previous year[30]. - Net income available to common shareholders was $25,469 thousand, down 62.1% from $67,329 thousand in the same quarter last year[38]. - Basic earnings per share attributable to common shareholders decreased to $0.50 from $1.31 year-over-year[38]. Segment Performance - The Research Models and Services (RMS) segment reported revenue of $213.1 million, a decrease of 3.5% from $220.9 million in Q1 2024[8]. - The Discovery and Safety Assessment (DSA) segment revenue was $592.6 million, down 2.1% from $605.5 million in Q1 2024[10]. - The Manufacturing segment revenue decreased to $178.5 million, a decline of 3.6% from $185.2 million in Q1 2024[13]. - Revenue for the Research Models and Services segment decreased to $213,073 thousand, down 3.8% from $220,907 thousand in the prior year[33]. - Non-GAAP operating income for the Discovery and Safety Assessment segment was $141,696 thousand, representing a 23.9% margin, compared to 23.5% in the previous year[33]. - Operating income for the Manufacturing Solutions segment was a loss of $(8,620) thousand, compared to a profit of $33,681 thousand in the prior year[33]. Guidance and Future Outlook - The company is increasing its 2025 guidance, now expecting revenue growth to be between -5.5% and -3.5%, improved from the previous guidance of -7.0% to -4.5%[16][17]. - Non-GAAP EPS guidance for 2025 is now projected to be between $9.30 and $9.80, up from the previous range of $9.10 to $9.60[17]. - The company noted a notable improvement in DSA booking activity, indicating demand stabilization despite broader market uncertainties[7]. - Non-GAAP revenue growth, organic, was reported at (1.8)%, with the Research Models and Services segment showing a decline of (2.5)%[40]. Cash Flow and Capital Expenditures - Cash and cash equivalents increased to $229.356 million from $194.606 million at the end of the previous quarter[31]. - Total assets rose to $7,582.366 million, up from $7,528.345 million at the end of December 2024[31]. - Long-term debt increased to $2,510.754 million from $2,240.205 million, indicating a rise in leverage[31]. - The company reported net cash provided by operating activities of $171.697 million, an increase from $129.888 million in the prior year[32]. - Capital expenditures for the quarter were $59.324 million, down from $79.144 million year-over-year[32]. - Capital expenditures for the Discovery and Safety Assessment segment were $34,521 thousand, down from $48,959 thousand in the previous year[33]. Other Financial Metrics - The company reported a total of $113,555 thousand in non-GAAP adjustments to operating income, compared to $61,441 thousand in the previous year[38]. - The company experienced a foreign exchange impact of 0.9% on reported revenue growth[40].

Wall Street expects a year-over-year decline in earnings on lower revenues when Charles River Laboratories (CRL) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on M ...

Charles River Laboratories International, Inc. (CRL) is scheduled to report first-quarter 2025 results on May 7, before market open.In the last reported quarter, the company’s adjusted earnings per share (EPS) of $2.66 surpassed the Zacks Consensus Estimate by 6.4%. Earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 10.22%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)CRL’s Q1 EstimatesThe Zacks Consensus Estimate for revenues is ...

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise.As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vas ...

It’s been a turbulent start to 2025 for investors. The market has faced a wave of selling pressure driven by surging tariffs, escalating geopolitical tensions, and growing fears of a global economic slowdown. The S&P 500, tracked by the popular SPDR ETF NYSEARCA: SPY, is now down 8% year-to-date and more than 12% off its 52-week high. However, there has been a glimmer of relief. After former President Trump announced a 90-day tariff pause for countries that refrained from retaliating against the U.S., the m ...